Ingevity Corporation (NGVT)
NYSE: NGVT · Real-Time Price · USD
73.11
+2.92 (4.16%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Ingevity Revenue
Ingevity had revenue of $314.10M in the quarter ending June 30, 2026, a decrease of -5.25%. This brings the company's revenue in the last twelve months to $1.16B, down -1.38% year-over-year. In the year 2025, Ingevity had annual revenue of $1.17B, down -2.71%.
Revenue (ttm)
$1.16B
Revenue Growth
-1.38%
P/S Ratio
2.17
Revenue / Employee
$773,533
Employees
1,500
Market Cap
2.51B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | -32.50M | -2.71% |
| Dec 31, 2024 | 1.20B | -15.40M | -1.27% |
| Dec 31, 2023 | 1.22B | -452.80M | -27.14% |
| Dec 31, 2022 | 1.67B | 276.80M | 19.89% |
| Dec 31, 2021 | 1.39B | 175.40M | 14.42% |
| Dec 31, 2020 | 1.22B | -76.80M | -5.94% |
| Dec 31, 2019 | 1.29B | 159.30M | 14.05% |
| Dec 31, 2018 | 1.13B | 161.20M | 16.58% |
| Dec 31, 2017 | 972.40M | 64.10M | 7.06% |
| Dec 31, 2016 | 908.30M | -50.00M | -5.22% |
| Dec 31, 2015 | 958.30M | -77.20M | -7.46% |
| Dec 31, 2014 | 1.04B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| The Chemours Company | 5.82B |
| Calumet | 4.17B |
| H.B. Fuller Company | 3.51B |
| Avient | 3.28B |
| Stepan Company | 2.43B |
| Minerals Technologies | 2.15B |
| Quaker Chemical | 1.98B |
| Ashland | 1.84B |
NGVT News
- 3 days ago - Ingevity Earnings Call Transcript: Q2 2026 - Transcripts
- 3 days ago - Ingevity Earnings release: Q2 2026 - Filings
- 3 days ago - Ingevity Slides: Q2 2026 - Filings
- 3 days ago - Ingevity Quarterly report: Q2 2026 - Filings
- 4 days ago - Ingevity reports Q2 adjusted EPS $1.74, consensus $1.33 - TheFly
- 4 days ago - Ingevity raises 2026 adjusted EPS view to $5.00-$5.45 from $4.70-$5.20 - TheFly
- 4 days ago - Ingevity reports second quarter 2026 financial results - Business Wire
- 17 days ago - Ingevity's Evotherm® P35 receives BASt approval in Germany - Business Wire